Related Experiment Video
Updated: Jul 26, 2025

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil
Hidenobu Tanihara1, Tetsuya Yamamoto2, Makoto Aihara3
1Department of Ophthalmology, Biei Municipal Hospital, 3-8-35 Naka-machi, Biei Town, Kamikawa-gun, Hokkaido, 071-0207, Japan. tanihara@pearl.ocn.ne.jp.
The fixed-dose combination of ripasudil-brimonidine (RBFC) effectively lowers intraocular pressure (IOP) compared to individual components. This combination drug offers a promising option for glaucoma management, potentially improving adherence.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Glaucoma treatment adherence is often poor with multidrug regimens.
- Fixed-dose combination (FDC) drugs may improve adherence and simplify treatment.
- The ripasudil-brimonidine fixed-dose combination (RBFC) is a novel ophthalmic solution combining a Rho kinase inhibitor and an α2-adrenoceptor agonist.
Purpose of the Study:
- To evaluate the pharmacologic effects of RBFC compared to its individual components, ripasudil and brimonidine.
- To assess the efficacy of RBFC in reducing intraocular pressure (IOP).
- To investigate the safety and tolerability of RBFC, including effects on conjunctival hyperemia and corneal endothelium.
Main Methods:
- A single-center, prospective, randomized, open-label, blinded endpoint study with a 3x3 crossover design was conducted.
- Healthy adult men were assigned to three groups, receiving consecutive 8-day administrations of RBFC, ripasudil, and brimonidine with washout periods.
- Endpoints included changes in IOP, conjunctival hyperemia, corneal endothelial cell morphology, pupil diameter, and pharmacokinetics.
Main Results:
- RBFC significantly reduced IOP from baseline at 1-hour post-instillation on days 1 and 8.
- RBFC demonstrated significantly greater IOP reductions than ripasudil or brimonidine at multiple time points.
- The most common adverse event was mild conjunctival hyperemia; transient corneal endothelial cell changes occurred with RBFC and ripasudil, but not brimonidine.
Conclusions:
- RBFC significantly reduced IOP compared to monotherapy with ripasudil or brimonidine.
- RBFC exhibited a combined pharmacologic profile of its individual components.
- RBFC represents a potentially effective and well-tolerated treatment option for glaucoma management.
Related Concept Videos
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Blinding
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...

